51 results
S-1
EX-10.15
KNTE
Kinnate Biopharma Inc
13 Nov 20
IPO registration
5:03pm
access to the Premises approximately fourteen (14) days prior to the Ready for Occupancy Date for the sole purpose of Tenant’s installing … Access. Tenant shall, subject to Landlord’s reasonable security requirements, Force Majeure, repairs and other de minimus interruptions, have access
DRS/A
EX-10.12
KNTE
Kinnate Biopharma Inc
16 Oct 20
Draft registration statement (amended)
12:00am
access to the Premises approximately fourteen (14) days prior to the Ready for Occupancy Date for the sole purpose of Tenant’s installing … Access. Tenant shall, subject to Landlord’s reasonable security requirements, Force Majeure, repairs and other de minimus interruptions, have access
8-K
EX-99.1
KNTE
Kinnate Biopharma Inc
7 Jun 21
Experienced leaders bring substantial clinical research, regulatory, and operational expertise in the biopharmaceutical industry to the Kinnate team
8:07am
the continued progress of our pipeline and advancing our mission of expanding access to targeted therapies for people living with hard-to-treat, genomically
DRS
EX-4.1
KNTE
Kinnate Biopharma Inc
4 Sep 20
Draft registration statement
12:00am
and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. No person or entity … access during normal business hours to all of the Company’s respective properties, books and records. Each Significant Holder shall have such other access
S-1
EX-4.1
KNTE
Kinnate Biopharma Inc
13 Nov 20
IPO registration
5:03pm
and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. No person or entity … access during normal business hours to all of the Company’s respective properties, books and records. Each Significant Holder shall have such other access
8-K
EX-99.2
21xwtiz8
17 Apr 23
Results of Operations and Financial Condition
3:15pm
S-1
EX-10.7
r548g8sn6
13 Nov 20
IPO registration
5:03pm
8-K
EX-99.1
3a2pctqheo coq479q6
13 May 21
Kinnate Biopharma Inc. Closes $35 Million Series A Financing
4:18pm
S-1
EX-10.8
4fwar
13 Nov 20
IPO registration
5:03pm
S-1
EX-10.5
k6kno888g9b5 ot6cuhj
13 Nov 20
IPO registration
5:03pm
S-1
EX-10.6
b45vvzq d9n
13 Nov 20
IPO registration
5:03pm
8-K
EX-10.1
g6f95q
7 Jun 21
Experienced leaders bring substantial clinical research, regulatory, and operational expertise in the biopharmaceutical industry to the Kinnate team
8:07am
DEF 14A
dk8mtdce9
30 Apr 21
Definitive proxy
9:13am
8-K
EX-2.1
5lcwt21
16 Feb 24
Entry into a Material Definitive Agreement
9:10am